BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects
- Conditions
- Healthy
- Interventions
- Drug: INX-08189 / Victrelis 800 mg TID X three daysDrug: Victrelis 800 mg TID x 3 daysDrug: INX-08189 50 mg QD X 5 daysDrug: Victrelis 800 mg TID with INX-08189 50 mg QDDrug: Placebo with Victrelis 800 mg
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT01471717
- Locations
- 🇺🇸
Prism Research, LLC, St Paul, Minnesota, United States
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
- Conditions
- Renal Cell CarcinomaClear-cell Metastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 194
- Registration Number
- NCT01472081
- Locations
- 🇺🇸
City Of Hope, Duarte, California, United States
🇺🇸Memorial Sloan Kettering Nassau, New York, New York, United States
🇺🇸Blumenthal Cancer Center, Charlotte, North Carolina, United States
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
- Conditions
- Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2011-11-15
- Last Posted Date
- 2017-04-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 124
- Registration Number
- NCT01471210
- Locations
- 🇺🇸
Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer - Non Small Cell
- Interventions
- Biological: IpilimumabBiological: Pemetrexed
- First Posted Date
- 2011-11-15
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9
- Registration Number
- NCT01471197
- Locations
- 🇺🇸
Marin Specialty Care, Inc., Greenbrae, California, United States
🇺🇸Medical And Surgical Specialists, Llc, Galesburg, Illinois, United States
🇺🇸Quincy Medical Group, Quincy, Illinois, United States
Belatacept in Renal Transplantation: Analyses Using Data From the Collaborative Transplant Study
- Conditions
- Kidney Transplantation
- First Posted Date
- 2011-11-15
- Last Posted Date
- 2017-09-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 89
- Registration Number
- NCT01471223
Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus
- Conditions
- Hepatitis C, Genotype 1
- Interventions
- First Posted Date
- 2011-11-15
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 549
- Registration Number
- NCT01471574
- Locations
- 🇺🇸
Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Icahn School Of Medicine At Mount Sinai, New York, New York, United States
🇺🇸San Francisco Gen Hosp, San Francisco, California, United States
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
- Conditions
- Crohn's Disease
- Interventions
- Drug: PlaceboDrug: BMS-936557 (Anti-IP-10 Antibody)
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 121
- Registration Number
- NCT01466374
- Locations
- 🇺🇸
Gastroenterology Research Of New Orleans, Hammond, Louisiana, United States
🇺🇸Southern California Medical Gastroenterology Group, Santa Monica, California, United States
🇺🇸University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States
Korean Post-marketing Surveillance for Sprycel®
- Conditions
- Leukemia, Myelomonocytic, ChronicLeukemia-Lymphoma
- First Posted Date
- 2011-11-03
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 670
- Registration Number
- NCT01464047
- Locations
- 🇰🇷
Local Institution, Seoul, Korea, Republic of
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
- First Posted Date
- 2011-10-26
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 106
- Registration Number
- NCT01460160
- Locations
- 🇺🇸
University Of Arkansas For Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Miller Children's and Women Hospital, Long Beach, California, United States
🇺🇸Mountain States Tumor Institute, Boise, Idaho, United States
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 320
- Registration Number
- NCT01455090
- Locations
- 🇵🇷
Fundacion De Investigacion De Diego, San Juan, Puerto Rico
🇺🇸James J Peters Vamc, The Bronx, New York, United States
🇺🇸Inova Fairfax Hospital, Falls Church, Virginia, United States